Cytotoxic therapy for AML. *Backbone dosing comments provided in article text. †No prospective data on this regimen in newly diagnosed patients; patients enrolled in institutional prospective trial of this regimen based on retrospective data. HCT-CI, Hematopoietic Cell Transplantation Comorbidity Index; MDS, myelodysplastic syndrome.